Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas
- PMID: 1352162
Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas
Abstract
Thirty-eight patients with refractory or relapsed non-Hodgkin's lymphoma (19 patients) or Hodgkin's disease (19 patients) were treated with salvage therapy. The peripheral stem cell collection was performed during hematologic recovery after myeloablative chemotherapy. In eight patients with Hodgkin's disease the number of CFU-GM collected was less than 0.5 x 10(4)/kg and these patients were excluded for stem cell transplantation. In the remaining 30 patients, a median of 4 x 10(4) CFU-GM/kg was collected (range 0.8-100 x 10(4)/kg) by three leukaphereses in 25 patients and six to 11 leukaphereses in five patients. Conditioning regimens were CBV (eight), BEAM (six), BEAC (10) and cyclophosphamide + total body irradiation (TBI) (six). Without TBI, the mean time for reaching a granulocyte count greater than 0.5 x 10(9)/l was 18 days and for a platelet count greater than 50 x 10(9)/l was 19 days in 23 out of 24 patients. With TBI, in five patients the mean time for reaching a granulocyte count greater tahn 0.5 x 10(9)/l was 37 days and for a platelet count greater than 50 x 10(9)/l was greater than 100 days. Complications were minor. There was only one toxic death. The outcome in these patients was similar to that observed in patients who received autologous bone marrow transplantation for advanced lymphomas. In conclusion, we observed good hematologic recovery except when TBI was used in the conditioning regimen.
Similar articles
-
High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.Bone Marrow Transplant. 1996 Feb;17(2):149-55. Bone Marrow Transplant. 1996. PMID: 8640159 Clinical Trial.
-
High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.Bone Marrow Transplant. 1996 May;17(5):715-21. Bone Marrow Transplant. 1996. PMID: 8733687 Clinical Trial.
-
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.Eur J Haematol. 2007 Feb;78(2):93-101. doi: 10.1111/j.1600-0609.2006.00796.x. Eur J Haematol. 2007. PMID: 17313557 Clinical Trial.
-
Intensive therapy and autotransplantation in Hodgkin's disease.Stem Cells. 1994 Sep;12(5):477-93. doi: 10.1002/stem.5530120504. Stem Cells. 1994. PMID: 7804123 Review.
-
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.Bone Marrow Transplant. 1996 Apr;17(4):503-7. Bone Marrow Transplant. 1996. PMID: 8722346 Review.
Cited by
-
Autografting with blood progenitor cells: predictive value of preapheresis blood cell counts on progenitor cell harvest and correlation of the reinfused cell dose with hematopoietic reconstitution.Ann Hematol. 1995 Nov;71(5):227-34. doi: 10.1007/BF01744372. Ann Hematol. 1995. PMID: 7492625
-
Evaluation of post-thaw CFU-GM: clinical utility and role in quality assessment of umbilical cord blood in patients receiving single unit transplant.Transfusion. 2020 Jan;60(1):144-154. doi: 10.1111/trf.15592. Epub 2019 Nov 22. Transfusion. 2020. PMID: 31756003 Free PMC article. Clinical Trial.
-
Autotransplants with peripheral blood stem cells and clinical results obtained in children: a review.Eur J Pediatr. 1993 Jul;152(7):546-54. doi: 10.1007/BF01954078. Eur J Pediatr. 1993. PMID: 7689055 Review.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Medical